Needham & Company Starts Generation Bio (GBIO) at Buy

Needham & Company analyst Gil Blum initiates coverage on Generation Bio (NASDAQ: GBIO) with a Buy rating and a price target of $50.00.

The analyst commented, "We believe GBIO is developing a new category of gene therapy with transformative potential for the industry. Gene therapy's ability to repair the underlying genetic cause of a disease offers therapeutic options in some of the most severe indications. However, fundamental challenges abound. Our KOL survey identified gene therapy durability as a key issue with current therapeutics. Generation's platform combines two innovative technologies: close ended DNA plasmids (ceDNA) and cell targeted lipid nanoparticles (ctLNPs). The ceDNA/ctLNP platform can potentially enable re-treatment of patients thus extending the durability of therapy."

For an analyst ratings summary and ratings history on Generation Bio click here. For more ratings news on Generation Bio click here.

Shares of Generation Bio closed at $31.79 yesterday.

You May Also Be Interested In

• Berenberg Starts Natwest Group PLC (NWG:LN) (NWG) at Buy
• Axis Capital Limited Upgrades Persistent Systems Ltd. (PSYS:IN) to Buy (1)
• Berenberg Starts Lloyds Banking Group Plc. (LLOY:LN) (LYG) at Hold